#10 OIPE 0590 0508

CRF Errors Corrected by the STIC Systems Branch

Serial Number: 09/801,185A

CRF Processing Date: 5/16/2002
Edited by:
Verified by: _____ (STIC staff)

ENTERED

- ☐ Changed a file from non-ASCII to ASCII
- ☐ Changed the margins in cases where the sequence text was "wrapped" down to the next line.
- ☐ Edited a format error in the Current Application Data section, specifically:

  _____

- ☐ Edited the Current Application Data section with the actual current number. The number inputted by the applicant was ☐ the prior application data; or ☐ other _____.
- ☐ Added the mandatory heading and subheadings for "Current Application Data".
- ☐ Edited the "Number of Sequences" field. The applicant spelled out a number instead of using an integer.
- ☐ Changed the spelling of a mandatory field (the headings or subheadings), specifically:

  _____

- ☐ Corrected the SEQ ID NO when obviously incorrect. The sequence numbers that were edited were:

  _____

- ☐ Inserted or corrected a nucleic number at the end of a nucleic line. SEQ ID NO's edited:

  _____

- ☐ Corrected subheading placement. All responses must be on the same line as each subheading. If the applicant placed a response below the subheading, this was moved to its appropriate place.
- ☐ Inserted colons after headings/subheadings. Headings edited included:

  _____

- ☐ Deleted extra, invalid, headings used by an applicant, specifically:

  _____

- ☐ Deleted: ☐ non-ASCII "garbage" at the beginning/end of files; ☐ secretary initials/filename at end of file; ☐ page numbers throughout text; ☐ other invalid text, such as _____.
- ☐ Inserted mandatory headings, specifically: _____
- ☐ Corrected an obvious error in the response, specifically:

  _____

- ☐ Edited identifiers where upper case is used but lower case is required, or vice versa.
- ☐ Corrected an error in the Number of Sequences field, specifically:

  _____

- ☐ A "Hard Page Break" code was inserted by the applicant. All occurrences had to be deleted.
- ☐ Deleted ***ending*** stop codon in amino acid sequences and adjusted the "(A)Length:" field accordingly (error due to a PatentIn bug). Sequences corrected: _____
- ☑ Other: Seq 37 - inserted '37' at end of (2) INFO. FOR SEQ ID NO: heading

*Examiner: The above corrections must be communicated to the applicant in the first Office Action. DO NOT send a copy of this form.

3/1/95

OIPE

RAW SEQUENCE LISTING DATE: 05/16/2002
PATENT APPLICATION: US/09/801,185A TIME: 19:08:26

Input Set : N:\Crf3\05072002\I801185A.raw.txt
Output Set: N:\CRF3\05162002\I801185A.raw

SEQUENCE LISTING

(1) GENERAL INFORMATION:
(i) APPLICANT: BASF Aktiengesellschaft
(ii) TITLE OF INVENTION: Human Antibodies that Bind Human TNFalpha
(iii) NUMBER OF SEQUENCES: 37
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: LAHIVE & COCKFIELD
(B) STREET: 28 State Street
(C) CITY: Boston
(D) STATE: Massachusetts
(E) COUNTRY: USA
(F) ZIP: 02109
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25
(vi) CURRENT APPLICATION DATA:
C--> **(A) APPLICATION NUMBER: US/09/801,185A**
C--> **(B) FILING DATE: 07-Mar-2001**
(C) CLASSIFICATION:
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 08/599,226
(B) FILING DATE: 09-FEB-1996
(A) APPLICATION NUMBER: US 60/031,476
(B) FILING DATE: 25-NOV-1996
(A) APPLICATION NUMBER: US 09/125,098
(B) FILING DATE: 07-AUG-1998
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: DeConti, Giulio A., Jr.
(B) REGISTRATION NUMBER: 31,503
(C) REFERENCE/DOCKET NUMBER: BBI-043CPUSCN
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (617)227-7400
(B) TELEFAX: (617)227-5941
(2) INFORMATION FOR SEQ ID NO: 1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 107 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(v) FRAGMENT TYPE: internal
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

RAW SEQUENCE LISTING DATE: 05/16/2002
PATENT APPLICATION: US/09/801,185A TIME: 19:08:26

Input Set : N:\Crf3\05072002\I801185A.raw.txt
Output Set: N:\CRF3\05162002\I801185A.raw

```
43          Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
44          1               5                   10                  15
45          Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Tyr
46                      20                  25                  30
47          Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
48                  35                  40                  45
49          Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50              50                  55                  60
51          Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
52          65                  70                  75                  80
53          Glu Asp Val Ala Thr Tyr Tyr Cys Gln Arg Tyr Asn Arg Ala Pro Tyr
54                          85                  90                  95
55          Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
56                      100                 105
58 (2) INFORMATION FOR SEQ ID NO: 2:
59      (i) SEQUENCE CHARACTERISTICS:
60          (A) LENGTH: 121 amino acids
61          (B) TYPE: amino acid
62          (D) TOPOLOGY: linear
63     (ii) MOLECULE TYPE: peptide
64      (v) FRAGMENT TYPE: internal
65     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
66          Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
67          1               5                   10                  15
68          Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
69                      20                  25                  30
70          Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
71                  35                  40                  45
72          Ser Ala Ile Thr Trp Asn Ser Gly His Ile Asp Tyr Ala Asp Ser Val
73              50                  55                  60
74          Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
75          65                  70                  75                  80
76          Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
77                          85                  90                  95
78          Ala Lys Val Ser Tyr Leu Ser Thr Ala Ser Ser Leu Asp Tyr Trp Gly
79                      100                 105                 110
80          Gln Gly Thr Leu Val Thr Val Ser Ser
81                  115                 120
83 (2) INFORMATION FOR SEQ ID NO: 3:
84      (i) SEQUENCE CHARACTERISTICS:
85          (A) LENGTH: 9 amino acids
86          (B) TYPE: amino acid
87          (D) TOPOLOGY: linear
88     (ii) MOLECULE TYPE: peptide
89      (v) FRAGMENT TYPE: internal
90     (ix) FEATURE:
91          (A) NAME/KEY: Modified-site
92          (B) LOCATION: 9
93          (D) OTHER INFORMATION: /note= "Xaa is Thr or Ala"
```

RAW SEQUENCE LISTING DATE: 05/16/2002
PATENT APPLICATION: **US/09/801,185A** TIME: 19:08:26

Input Set : **N:\Crf3\05072002\I801185A.raw.txt**
Output Set: **N:\CRF3\05162002\I801185A.raw**

```
     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
W--> Gln Arg Tyr Asn Arg Ala Pro Tyr Xaa
     1               5
(2) INFORMATION FOR SEQ ID NO: 4:
      (i) SEQUENCE CHARACTERISTICS:
           (A) LENGTH: 12 amino acids
           (B) TYPE: amino acid
           (D) TOPOLOGY: linear
     (ii) MOLECULE TYPE: peptide
      (v) FRAGMENT TYPE: internal
     (ix) FEATURE:
           (A) NAME/KEY: Modified-site
           (B) LOCATION: 12
           (D) OTHER INFORMATION: /note= "Xaa is Tyr or Asn"
     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
W--> Val Ser Tyr Leu Ser Thr Ala Ser Ser Leu Asp Xaa
     1               5                   10
(2) INFORMATION FOR SEQ ID NO: 5:
      (i) SEQUENCE CHARACTERISTICS:
           (A) LENGTH: 7 amino acids
           (B) TYPE: amino acid
           (D) TOPOLOGY: linear
     (ii) MOLECULE TYPE: peptide
      (v) FRAGMENT TYPE: internal
     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
           Ala Ala Ser Thr Leu Gln Ser
           1               5
(2) INFORMATION FOR SEQ ID NO: 6:
      (i) SEQUENCE CHARACTERISTICS:
           (A) LENGTH: 17 amino acids
           (B) TYPE: amino acid
           (D) TOPOLOGY: linear
     (ii) MOLECULE TYPE: peptide
      (v) FRAGMENT TYPE: internal
     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:
           Ala Ile Thr Trp Asn Ser Gly His Ile Asp Tyr Ala Asp Ser Val Glu
           1               5                   10                  15
           Gly
(2) INFORMATION FOR SEQ ID NO: 7:
      (i) SEQUENCE CHARACTERISTICS:
           (A) LENGTH: 11 amino acids
           (B) TYPE: amino acid
           (D) TOPOLOGY: linear
     (ii) MOLECULE TYPE: peptide
      (v) FRAGMENT TYPE: internal
     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:
           Arg Ala Ser Gln Gly Ile Arg Asn Tyr Leu Ala
           1               5                   10
(2) INFORMATION FOR SEQ ID NO: 8:
```

RAW SEQUENCE LISTING DATE: 05/16/2002
PATENT APPLICATION: US/09/801,185A TIME: 19:08:26

Input Set : N:\Crf3\05072002\I801185A.raw.txt
Output Set: N:\CRF3\05162002\I801185A.raw

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(v) FRAGMENT TYPE: internal
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Asp Tyr Ala Met His
1 5

(2) INFORMATION FOR SEQ ID NO: 9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 107 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(v) FRAGMENT TYPE: internal
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Ile Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro Tyr
85 90 95
Ala Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105

(2) INFORMATION FOR SEQ ID NO: 10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 121 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(v) FRAGMENT TYPE: internal
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
20 25 30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Asp Trp Val
35 40 45
Ser Ala Ile Thr Trp Asn Ser Gly His Ile Asp Tyr Ala Asp Ser Val
50 55 60
Glu Gly Arg Phe Ala Val Ser Arg Asp Asn Ala Lys Asn Ala Leu Tyr
65 70 75 80

RAW SEQUENCE LISTING DATE: 05/16/2002
PATENT APPLICATION: US/09/801,185A TIME: 19:08:26

Input Set : N:\Crf3\05072002\I801185A.raw.txt
Output Set: N:\CRF3\05162002\I801185A.raw

```
199          Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys
200                          85                  90                  95
201          Thr Lys Ala Ser Tyr Leu Ser Thr Ser Ser Ser Leu Asp Asn Trp Gly
202                     100                 105                 110
203          Gln Gly Thr Leu Val Thr Val Ser Ser
204                  115                 120
206 (2) INFORMATION FOR SEQ ID NO: 11:
207      (i) SEQUENCE CHARACTERISTICS:
208           (A) LENGTH: 9 amino acids
209           (B) TYPE: amino acid
210           (D) TOPOLOGY: linear
211     (ii) MOLECULE TYPE: peptide
212      (v) FRAGMENT TYPE: internal
213     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:
214           Gln Lys Tyr Asn Ser Ala Pro Tyr Ala
215           1               5
217 (2) INFORMATION FOR SEQ ID NO: 12:
218      (i) SEQUENCE CHARACTERISTICS:
219           (A) LENGTH: 9 amino acids
220           (B) TYPE: amino acid
221           (D) TOPOLOGY: linear
222     (ii) MOLECULE TYPE: peptide
223      (v) FRAGMENT TYPE: internal
224     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:
225           Gln Lys Tyr Asn Arg Ala Pro Tyr Ala
226           1               5
228 (2) INFORMATION FOR SEQ ID NO: 13:
229      (i) SEQUENCE CHARACTERISTICS:
230           (A) LENGTH: 9 amino acids
231           (B) TYPE: amino acid
232           (D) TOPOLOGY: linear
233     (ii) MOLECULE TYPE: peptide
234      (v) FRAGMENT TYPE: internal
235     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:
236           Gln Lys Tyr Gln Arg Ala Pro Tyr Thr
237           1               5
239 (2) INFORMATION FOR SEQ ID NO: 14:
240      (i) SEQUENCE CHARACTERISTICS:
241           (A) LENGTH: 9 amino acids
242           (B) TYPE: amino acid
243           (D) TOPOLOGY: linear
244     (ii) MOLECULE TYPE: peptide
245      (v) FRAGMENT TYPE: internal
246     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:
247           Gln Lys Tyr Ser Ser Ala Pro Tyr Thr
248           1               5
250 (2) INFORMATION FOR SEQ ID NO: 15:
251      (i) SEQUENCE CHARACTERISTICS:
252           (A) LENGTH: 9 amino acids
```

OIPE

RAW SEQUENCE LISTING DATE: 05/16/2002
PATENT APPLICATION: US/09/801,185A TIME: 18:59:57

Input Set : N:\Crf3\05072002\I801185A.raw
Output Set: N:\CRF3\05162002\I801185A.raw

Does Not Comply
Corrected Diskette Needed

SEQUENCE LISTING

1 (1) GENERAL INFORMATION:
2 (i) APPLICANT: BASF Aktiengesellschaft
3 (ii) TITLE OF INVENTION: Human Antibodies that Bind Human TNFalpha
4 (iii) NUMBER OF SEQUENCES: 37
5 (iv) CORRESPONDENCE ADDRESS:
6 (A) ADDRESSEE: LAHIVE & COCKFIELD
7 (B) STREET: 28 State Street
8 (C) CITY: Boston
9 (D) STATE: Massachusetts
10 (E) COUNTRY: USA
11 (F) ZIP: 02109
12 (v) COMPUTER READABLE FORM:
13 (A) MEDIUM TYPE: Floppy disk
14 (B) COMPUTER: IBM PC compatible
15 (C) OPERATING SYSTEM: PC-DOS/MS-DOS
16 (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
17 (vi) CURRENT APPLICATION DATA:
C--> 18 **(A) APPLICATION NUMBER: US/09/801,185A**
C--> 19 **(B) FILING DATE: 07-Mar-2001**
20 (C) CLASSIFICATION:
21 (vii) PRIOR APPLICATION DATA:
22 (A) APPLICATION NUMBER: US 08/599,226
23 (B) FILING DATE: 09-FEB-1996
24 (A) APPLICATION NUMBER: US 60/031,476
25 (B) FILING DATE: 25-NOV-1996
26 (A) APPLICATION NUMBER: US 09/125,098
27 (B) FILING DATE: 07-AUG-1998
28 (viii) ATTORNEY/AGENT INFORMATION:
29 (A) NAME: DeConti, Giulio A., Jr.
30 (B) REGISTRATION NUMBER: 31,503
31 (C) REFERENCE/DOCKET NUMBER: BBI-043CPUSCN
32 (ix) TELECOMMUNICATION INFORMATION:
33 (A) TELEPHONE: (617)227-7400
34 (B) TELEFAX: (617)227-5941

ERRORED SEQUENCES

E--> 496 (2) INFORMATION FOR SEQ ID NO: 37: Insert
497 (i) SEQUENCE CHARACTERISTICS:
498 (A) LENGTH: 363 base pairs
499 (B) TYPE: nucleic acid

RAW SEQUENCE LISTING DATE: 05/16/2002
PATENT APPLICATION: **US/09/801,185A** TIME: 18:59:57

Input Set : **N:\Crf3\05072002\I801185A.raw**
Output Set: **N:\CRF3\05162002\I801185A.raw**

(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

GAGGTGCAGC TGGTGGAGTC TGGGGGAGGC TTGGTACAGC CCGGCAGGTC CCTGAGACTC 60
TCCTGTGCGG CCTCTGGATT CACCTTTGAT GATTATGCCA TGCACTGGGT CCGGCAAGCT 120
CCAGGGAAGG GCCTGGAATG GGTCTCAGCT ATCACTTGGA ATAGTGGTCA CATAGACTAT 180
GCGGACTCTG TGGAGGGCCG ATTCACCATC TCCAGAGACA ACGCCAAGAA CTCCCTGTAT 240
CTGCAAATGA ACAGTCTGAG AGCTGAGGAT ACGGCCGTAT ATTACTGTGC GAAAGTCTCG 300
TACCTTAGCA CCGCGTCCTC CCTTGACTAT TGGGGCCAAG GTACCCTGGT CACCGTCTCG 360
AGT 363

VERIFICATION SUMMARY DATE: 05/16/2002
PATENT APPLICATION: **US/09/801,185A** TIME: 18:59:58

Input Set : **N:\Crf3\05072002\I801185A.raw**
Output Set: **N:\CRF3\05162002\I801185A.raw**

L:18 M:220 C: Keyword misspelled or invalid format, [(A) APPLICATION NUMBER:]
L:19 M:220 C: Keyword misspelled or invalid format, [(B) FILING DATE:]
L:95 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3 after pos.:0
L:110 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4 after pos.:0
L:496 M:202 E: (16) Value must be an Integer, Data=[]
L:503 M:212 E: (34) Invalid or duplicate Sequence ID Number, Data=[37:]